NCT00709722 - Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Lupus Nephritis

Interventions

DRUG

NKT-01

SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.

Trial Locations (6)

Universitatsklinikum Charite, Berlin

General Faculty Hospital, Prague

Universitat Frankfurt, Frankfurt

University Hospital Mannheim, Heidelberg University, Mannheim

University of Heidelberg, Heidelberg

University of Regensburg, Regensburg